Shares of Aldeyra Therapeutics Inc. (ALDX) are surging over 18% in pre-market today, after the company announced positive top-line Phase 1 clinical trial results for ADX-629, a first-in-class orally available reactive aldehyde species (RASP) inhibitor in development for the treatment of systemic immune-mediated diseases. Aldeyra also announced Phase 2 clinical development plans for ADX-629.
from RTT - Before the Bell https://ift.tt/2VqoFkc
via IFTTT
No comments:
Post a Comment